Biod Selected in a Market Where 95% of AI Drug Pilots Fail(venturesquare.net)
Writing language: KoreanRead in the original language
Plain summary
- Biod was selected for the Ministry of SMEs and Startups' 'Super Gap 1000+' program, securing up to 600 million KRW in funding.
- It is welcome news for early-stage bio teams because they can continue research without giving up equity.
- By deciding which tasks in drug development to improve and which experiments to finish before the funding runs out, the content to show to the next investor becomes much clearer.
Have you run into something like this? Tell us in a line or two what you did. You do not need to know the product.